IRVINE, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) announced today that its management team will participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.
About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.
Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
Real-Time Revenue Cycle Management and Clinical Workflow Optimization for Radiology Practices to Debut at RSNA…
SAN DIEGO, Nov. 25, 2024 /PRNewswire/ -- Cortechs.ai, a leading provider of AI-powered imaging solutions,…
ROSEMONT, Ill., Nov. 25, 2024 /PRNewswire/ -- The American Association of Nurse Anesthesiology (AANA) has…
Specialized for veterinary care, SmartRotate™ for Equine automatically presents each image in the correct orientation,…
New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy…
PLANO, Texas, Nov. 25, 2024 /PRNewswire/ -- Bimini Health Tech has received United States 510k…